Do analysts prefer DXRX or ABDX?

Diaceutics currently has a consensus price target of GBX 205.33, indicating a potential upside of 44.15%. Given Diaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Diaceutics is more favorable than Abingdon Health. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Diaceutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Abingdon Health 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ABDX or GDR more profitable?

Abingdon Health has a net margin of -33.88% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -55.91% beat genedrive's return on equity. Company Net Margins Return on Equity Return on Assets Abingdon Health -33.88% -55.91% -17.93% genedrive -500.75% -1,044.57% -74.09%

Is GENI or ABDX more profitable?

Abingdon Health has a net margin of -33.88% compared to GENinCode's net margin of -185.47%. Abingdon Health's return on equity of -55.91% beat GENinCode's return on equity. Company Net Margins Return on Equity Return on Assets GENinCode -185.47% -409.40% -63.99% Abingdon Health -33.88% -55.91% -17.93%

Which has better earnings and valuation, AGL or ABDX?

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ANGLE £2.62M 2.89 -£21.76M -£4.80 N/A Abingdon Health £9.57M 3.06 -£796.37K -£0.81 N/A

Is AGL or ABDX more profitable?

Abingdon Health has a net margin of -33.88% compared to ANGLE's net margin of -732.40%. Abingdon Health's return on equity of -55.91% beat ANGLE's return on equity. Company Net Margins Return on Equity Return on Assets ANGLE -732.40% -89.82% -29.89% Abingdon Health -33.88% -55.91% -17.93%

Abingdon Health (ABDX) Competitors

GBX 11.65 -0.24 (-2.01%)

As of 11:48 AM Eastern

Compare

ABDX vs. DXRX, GDR, YGEN, GENI, and AGL

Should you buy Abingdon Health stock or one of its competitors? MarketBeat compares Abingdon Health with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Abingdon Health include Diaceutics (DXRX), genedrive (GDR), Yourgene Health (YGEN), GENinCode (GENI), and ANGLE (AGL). These companies are all part of the "diagnostics & research" industry.

How does Abingdon Health compare to Diaceutics?

Diaceutics (LON:DXRX) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, media sentiment, dividends, profitability, institutional ownership and valuation.

32.3% of Diaceutics shares are held by institutional investors. Comparatively, 3.7% of Abingdon Health shares are held by institutional investors. 26.3% of Diaceutics shares are held by company insiders. Comparatively, 8.0% of Abingdon Health shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Diaceutics has a beta of 0.893, meaning that its share price is 11% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.117, meaning that its share price is 88% less volatile than the broader market.

Diaceutics has a net margin of 0.25% compared to Abingdon Health's net margin of -33.88%. Diaceutics' return on equity of 0.25% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Diaceutics	0.25%	0.25%	-6.06%
Abingdon Health	-33.88%	-55.91%	-17.93%

Abingdon Health has lower revenue, but higher earnings than Diaceutics. Abingdon Health is trading at a lower price-to-earnings ratio than Diaceutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Diaceutics	£38.44M	3.14	-£2.84M	£0.11	1,294.91
Abingdon Health	£9.57M	3.06	-£796.37K	-£0.81	N/A

Diaceutics currently has a consensus price target of GBX 205.33, indicating a potential upside of 44.15%. Given Diaceutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Diaceutics is more favorable than Abingdon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Diaceutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Abingdon Health	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Diaceutics had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for Diaceutics and 0 mentions for Abingdon Health. Diaceutics' average media sentiment score of 1.00 beat Abingdon Health's score of 0.00 indicating that Diaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
Diaceutics	Positive
Abingdon Health	Neutral

Summary

Diaceutics beats Abingdon Health on 15 of the 16 factors compared between the two stocks.

How does Abingdon Health compare to genedrive?

Abingdon Health (LON:ABDX) and genedrive (LON:GDR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

3.7% of Abingdon Health shares are held by institutional investors. Comparatively, 0.1% of genedrive shares are held by institutional investors. 8.0% of Abingdon Health shares are held by insiders. Comparatively, 29.0% of genedrive shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Abingdon Health has a net margin of -33.88% compared to genedrive's net margin of -500.75%. Abingdon Health's return on equity of -55.91% beat genedrive's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abingdon Health	-33.88%	-55.91%	-17.93%
genedrive	-500.75%	-1,044.57%	-74.09%

Abingdon Health has higher revenue and earnings than genedrive. Abingdon Health is trading at a lower price-to-earnings ratio than genedrive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abingdon Health	£9.57M	3.06	-£796.37K	-£0.81	N/A
genedrive	£929K	21.34	-£21.22M	-£0.79	N/A

Abingdon Health has a beta of 0.117, meaning that its share price is 88% less volatile than the broader market. Comparatively, genedrive has a beta of -0.04, meaning that its share price is 104% less volatile than the broader market.

In the previous week, genedrive had 1 more articles in the media than Abingdon Health. MarketBeat recorded 1 mentions for genedrive and 0 mentions for Abingdon Health. genedrive's average media sentiment score of 1.27 beat Abingdon Health's score of 0.00 indicating that genedrive is being referred to more favorably in the news media.

Company	Overall Sentiment
Abingdon Health	Neutral
genedrive	Positive

Summary

Abingdon Health beats genedrive on 7 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to Yourgene Health?

Yourgene Health (LON:YGEN) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

Abingdon Health has lower revenue, but higher earnings than Yourgene Health. Abingdon Health is trading at a lower price-to-earnings ratio than Yourgene Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yourgene Health	£29.67M	0.00	-£8.17M	-£0.01	N/A
Abingdon Health	£9.57M	3.06	-£796.37K	-£0.81	N/A

Yourgene Health has a net margin of -27.55% compared to Abingdon Health's net margin of -33.88%. Yourgene Health's return on equity of -27.06% beat Abingdon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yourgene Health	-27.55%	-27.06%	-6.71%
Abingdon Health	-33.88%	-55.91%	-17.93%

Yourgene Health has a beta of 0.86, suggesting that its share price is 14% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.117, suggesting that its share price is 88% less volatile than the broader market.

23.3% of Yourgene Health shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 64.4% of Yourgene Health shares are owned by company insiders. Comparatively, 8.0% of Abingdon Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Yourgene Health's average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company	Overall Sentiment
Yourgene Health	Neutral
Abingdon Health	Neutral

Summary

Yourgene Health beats Abingdon Health on 8 of the 10 factors compared between the two stocks.

How does Abingdon Health compare to GENinCode?

GENinCode (LON:GENI) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, media sentiment, profitability, valuation and institutional ownership.

Abingdon Health has higher revenue and earnings than GENinCode. Abingdon Health is trading at a lower price-to-earnings ratio than GENinCode, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GENinCode	£2.91M	2.36	-£6.10M	-£2.35	N/A
Abingdon Health	£9.57M	3.06	-£796.37K	-£0.81	N/A

GENinCode has a beta of 0.588, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.117, meaning that its stock price is 88% less volatile than the broader market.

Abingdon Health has a net margin of -33.88% compared to GENinCode's net margin of -185.47%. Abingdon Health's return on equity of -55.91% beat GENinCode's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GENinCode	-185.47%	-409.40%	-63.99%
Abingdon Health	-33.88%	-55.91%	-17.93%

In the previous week, GENinCode had 3 more articles in the media than Abingdon Health. MarketBeat recorded 3 mentions for GENinCode and 0 mentions for Abingdon Health. Abingdon Health's average media sentiment score of 0.00 beat GENinCode's score of -0.32 indicating that Abingdon Health is being referred to more favorably in the news media.

Company	Overall Sentiment
GENinCode	Neutral
Abingdon Health	Neutral

4.5% of GENinCode shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 8.7% of GENinCode shares are owned by insiders. Comparatively, 8.0% of Abingdon Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Abingdon Health beats GENinCode on 8 of the 13 factors compared between the two stocks.

How does Abingdon Health compare to ANGLE?

ANGLE (LON:AGL) and Abingdon Health (LON:ABDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Abingdon Health has higher revenue and earnings than ANGLE. Abingdon Health is trading at a lower price-to-earnings ratio than ANGLE, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANGLE	£2.62M	2.89	-£21.76M	-£4.80	N/A
Abingdon Health	£9.57M	3.06	-£796.37K	-£0.81	N/A

ANGLE has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Abingdon Health has a beta of 0.117, suggesting that its stock price is 88% less volatile than the broader market.

Abingdon Health has a net margin of -33.88% compared to ANGLE's net margin of -732.40%. Abingdon Health's return on equity of -55.91% beat ANGLE's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ANGLE	-732.40%	-89.82%	-29.89%
Abingdon Health	-33.88%	-55.91%	-17.93%

17.5% of ANGLE shares are owned by institutional investors. Comparatively, 3.7% of Abingdon Health shares are owned by institutional investors. 2.7% of ANGLE shares are owned by company insiders. Comparatively, 8.0% of Abingdon Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, ANGLE's average media sentiment score of 0.00 equaled Abingdon Health'saverage media sentiment score.

Company	Overall Sentiment
ANGLE	Neutral
Abingdon Health	Neutral

Summary

Abingdon Health beats ANGLE on 8 of the 11 factors compared between the two stocks.

Get Abingdon Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABDX vs. The Competition

Export

Metric	Abingdon Health	Diagnostics & Research Industry	Medical Sector	LON Exchange
Market Cap	£29.25M	£41.88M	£6.50B	£2.72B
Dividend Yield	N/A	3.34%	2.67%	6.13%
P/E Ratio	-14.38	76.91	24.65	366.57
Price / Sales	3.06	618.54	498.98	86,640.48
Price / Cash	2.25	11.42	43.05	27.87
Price / Book	16.01	3.46	10.43	7.62
Net Income	-£796.37K	£334.07B	£3.56B	£5.89B
7 Day Performance	-7.36%	-5.31%	-1.39%	-1.31%
1 Month Performance	-4.58%	-8.15%	0.86%	0.85%
1 Year Performance	79.23%	1.00%	19.42%	70.33%

Abingdon Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABDX Abingdon Health	N/A	GBX 11.65 -2.0%	N/A	+74.3%	£29.25M	£9.57M	N/A	84	Gap Up
DXRX Diaceutics	2.799 of 5 stars	GBX 137.90 -4.2%	GBX 205.33 +48.9%	+11.3%	£116.70M	£38.44M	1,253.64	151	Positive News High Trading Volume
GDR genedrive	N/A	GBX 1.22 -2.4%	N/A	-12.4%	£19.59M	£929K	N/A	43	Gap Up
YGEN Yourgene Health	N/A	N/A	N/A	N/A	£16.43M	£29.67M	N/A	253
GENI GENinCode	N/A	GBX 1.05 -8.7%	N/A	-56.8%	£7.61M	£2.91M	N/A	2,300	Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:ABDX) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abingdon Health (ABDX) Competitors

ABDX vs. DXRX, GDR, YGEN, GENI, and AGL

How does Abingdon Health compare to Diaceutics?

Summary

How does Abingdon Health compare to genedrive?

Summary

How does Abingdon Health compare to Yourgene Health?

Summary

How does Abingdon Health compare to GENinCode?

Summary

How does Abingdon Health compare to ANGLE?

Summary

Media Sentiment Over Time

ABDX vs. The Competition

Abingdon Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Abingdon Health (ABDX) Competitors

ABDX vs. DXRX, GDR, YGEN, GENI, and AGL

How does Abingdon Health compare to Diaceutics?

Do institutionals & insiders have more ownership in DXRX or ABDX?

Which has more risk & volatility, DXRX or ABDX?

Is DXRX or ABDX more profitable?

Which has better valuation and earnings, DXRX or ABDX?

Do analysts prefer DXRX or ABDX?

Does the media favor DXRX or ABDX?

Summary

How does Abingdon Health compare to genedrive?

Do insiders & institutionals have more ownership in ABDX or GDR?

Is ABDX or GDR more profitable?

Which has stronger valuation and earnings, ABDX or GDR?

Which has more risk & volatility, ABDX or GDR?

Does the media refer more to ABDX or GDR?

Summary

How does Abingdon Health compare to Yourgene Health?

Which has better earnings & valuation, YGEN or ABDX?

Is YGEN or ABDX more profitable?

Which has more risk & volatility, YGEN or ABDX?

Do institutionals & insiders have more ownership in YGEN or ABDX?

Does the media refer more to YGEN or ABDX?

Summary

How does Abingdon Health compare to GENinCode?

Which has preferable valuation & earnings, GENI or ABDX?

Which has more risk and volatility, GENI or ABDX?

Is GENI or ABDX more profitable?

Does the media favor GENI or ABDX?

Do insiders and institutionals hold more shares of GENI or ABDX?

Summary

How does Abingdon Health compare to ANGLE?

Which has better earnings and valuation, AGL or ABDX?

Which has more risk & volatility, AGL or ABDX?

Is AGL or ABDX more profitable?

Do institutionals & insiders have more ownership in AGL or ABDX?

Does the media prefer AGL or ABDX?

Summary

Media Sentiment Over Time

ABDX vs. The Competition

Abingdon Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools